Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
KymriahⓇ - CD19 CAR-T
Appendix
References
Innovation: Clinical trials
Abbreviations
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03570892 BELINDA (CCTL019H2301)
2nd line Diffuse large B-cell lymphoma (DLBCL)
Phase 3
318
Event-free Survival (EFS)
Tisagenlecleucel versus standard of care
Adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of
rituximab and anthracycline- containing frontline immunochemotherapy
Target Patients
Read-out Milestone(s)
9 Jul 2021 (actual)
Publication
Bishop et al at SITC 2019
Abstract submission TBD
NCT03876769 CASSIOPEIA (CCTL019G2201J)
1st line high risk acute lymphoblastic leukemia (ALL)
Phase 2
160
Disease Free Survival (DFS)
Single-arm study of tisagenlecleucel
Pediatric and young adult patients with 1st line high risk ALL
2025
TBD
106 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation